{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:15:17Z","timestamp":1793502917034,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T00:00:00Z","timestamp":1494633600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["15\/576"],"award-info":[{"award-number":["15\/576"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s00223-017-0288-x","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T22:37:23Z","timestamp":1494628643000},"page":"371-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":114,"title":["Bone Loss After Denosumab: Only Partial Protection with Zoledronate"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5458","authenticated-orcid":false,"given":"Ian R.","family":"Reid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislav","family":"Mihov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory D.","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,13]]},"reference":[{"key":"288_CR1","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"key":"288_CR2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222\u2013229","journal-title":"Bone"},{"issue":"suppl","key":"288_CR3","first-page":"S408","volume":"31","author":"AW Popp","year":"2016","unstructured":"Popp AW, Buffat H, Senn C et al (2016) Rebound-associated bone loss after non-renewal of long-term denosumab treatment offsets 10-year gains at the total hip within 12 months. J Bone Miner Res 31(suppl):S408","journal-title":"J Bone Miner Res"},{"key":"288_CR4","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics. Osteoporos Int 27:1917\u20131921","journal-title":"Osteoporos Int"},{"key":"288_CR5","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D et al (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925","journal-title":"Osteoporos Int"},{"key":"288_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3110","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2017) Clinical features of 24 patients with rebound-associated vertebral fractures following denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. doi:\n                        10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"288_CR7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s00198-015-3459-5","volume":"27","author":"AD Anastasilakis","year":"2016","unstructured":"Anastasilakis AD, Makras P (2016) Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int 27:1929\u20131930","journal-title":"Osteoporos Int"},{"key":"288_CR8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/jc.2017-00096","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D et al (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358","journal-title":"J Clin Endocrinol Metab"},{"key":"288_CR9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET et al (2012) Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326","journal-title":"Osteoporos Int"},{"key":"288_CR10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765","journal-title":"N Engl J Med"},{"key":"288_CR11","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","volume":"26","author":"S Papapoulos","year":"2015","unstructured":"Papapoulos S, Lippuner K, Roux C et al (2015) The effect of 8 or 5\u00a0years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int 26:2773\u20132783","journal-title":"Osteoporos Int"},{"key":"288_CR12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland MJ, Horne A et al (2012) Five years of anti-resorptive activity after a single dose of zoledronate\u2014results from a randomized double-blind placebo-controlled trial. Bone 50:1389\u20131393","journal-title":"Bone"},{"key":"288_CR13","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","volume":"114","author":"M McClung","year":"2009","unstructured":"McClung M, Miller P, Recknor C et al (2009) Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass a randomized controlled trial. Obstet Gynecol 114:999\u20131007","journal-title":"Obstet Gynecol"},{"key":"288_CR14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.103","volume":"25","author":"A Grey","year":"2010","unstructured":"Grey A, Bolland M, Wattie D et al (2010) Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial. J Bone Miner Res 25:2251\u20132255","journal-title":"J Bone Miner Res"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-017-0288-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,6]],"date-time":"2017-09-06T18:51:12Z","timestamp":1504723872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-017-0288-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,13]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["288"],"URL":"https:\/\/doi.org\/10.1007\/s00223-017-0288-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727625402.793539868","asserted-by":"object"}]},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,13]]}}}